RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Rhea-AI Summary

RenovaroCube (NASDAQ: RENB), a leader in AI-driven cancer diagnostics, presented groundbreaking research at the Molecular Analysis for Precision Oncology Congress on October 16, 2024. The study explores the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) from blood plasma to detect copy number alterations (CNAs) in lung cancer patients.

Key findings include:

• Effective capture of significant CNAs in lung cancer tissues
• Potential for estimating tumor fractions
• Reduced need for invasive tissue biopsies

This research represents a significant advancement in oncology, offering potential improvements in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. RenovaroCube continues to advance precision medicine through innovative technologies, aiming to provide more effective, patient-centered cancer care.

Positive

• Presentation of innovative research at a major oncology congress
• Development of non-invasive cancer diagnostic technology using Oxford Nanopore sequencing
• Potential for improved cancer monitoring and targeted therapy

Negative

• None.

Insights

Medical Research Analyst

This study presents promising advancements in non-invasive cancer diagnostics using Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA). The ability to detect copy number alterations (CNAs) in lung cancer patients through blood plasma analysis is a significant step towards reducing the need for invasive tissue biopsies. CNAs are important for cancer monitoring, prognosis prediction and targeted therapy. The technology's potential to estimate tumor fractions could improve cancer progression tracking. While this research is exciting, it's important to note that it's still in the presentation stage and not yet implemented in clinical practice. The impact on RenovaroCube's 137 million market cap company may be in the short term, but long-term prospects could be promising if the technology proves successful in larger studies and gains regulatory approval.

Oncology Expert

The presentation of this research at the Molecular Analysis for Precision Oncology Congress is noteworthy, but its immediate clinical impact is The use of Oxford Nanopore sequencing on cfDNA to detect CNAs in lung cancer patients is an innovative approach that could potentially revolutionize cancer diagnostics. However, several steps remain before this technology can be widely adopted in clinical settings. These include validation in larger patient cohorts, comparison with current gold standard methods and regulatory approvals. While the potential to reduce invasive biopsies is significant, oncologists will need robust evidence of accuracy and reliability before incorporating this method into standard practice. For investors, this represents early-stage research with long-term potential rather than an immediate game-changer for RenovaroCube's market position or revenue stream.

AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024.

This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping.

“The research demonstrates that Oxford Nanopore sequencing of cell-free DNA from blood plasma can effectively capture significant copy number alterations (CNAs), which characterize the copy number landscape of lung cancer tissues—traditionally assessed through tissue biopsy,” said Khashayar Roohollahi, senior scientist at RenovaroCube.

Furthermore, CNAs can be used to estimate tumor fractions which is useful for predicting cancer progression and monitoring. The study emphasizes the potential of this technology in reducing the need for invasive tissue biopsies, a significant advancement in oncology.

Read more about the poster: https://renovarogroup.com/novel-insights-on-non-invasive-cancer-diagnostics-poster/

RenovaroCube remains committed to advancing precision medicine through innovative research and technologies, offering hope for more effective, patient-centered cancer care.

About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments utilizing non-invasive liquid biobsy. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

About MAP
MAP focuses on current and emerging approaches in precision oncology, highlights successes and challenges, and proposes potential solutions in clinical research and practice.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com and STarsh@Renovarogroup.com

Source: Renovaro Inc.

FAQ

What technology did RenovaroCube (RENB) present at the Molecular Analysis for Precision Oncology Congress on October 16, 2024?

RenovaroCube presented research on using Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) from blood plasma to detect copy number alterations (CNAs) in lung cancer patients.

How can the technology presented by RenovaroCube (RENB) benefit cancer diagnostics?

The technology can potentially reduce the need for invasive tissue biopsies, improve cancer monitoring, aid in prognosis prediction, enable targeted therapy, and allow for precise cancer subtyping.

What are the key findings of RenovaroCube's (RENB) research presented on October 16, 2024?

The research showed that Oxford Nanopore sequencing of cfDNA can effectively capture significant copy number alterations (CNAs) in lung cancer tissues and can be used to estimate tumor fractions, which is useful for predicting cancer progression and monitoring.

When and where did RenovaroCube (RENB) present its latest research on non-invasive cancer diagnostics?

RenovaroCube presented its research at the Molecular Analysis for Precision Oncology Congress on October 16, 2024.